Diabetes Leadership Edge: Module 6 - The Convergence of Cardiovascular Risk Reduction and Glucose Management in Patients with Type 2 Diabetes

This interactive activity explores the relationship between type 2 Diabetes (T2D) and cardiovascular disease and is part of AAPA’s curriculum known as Diabetes Leadership Edge.

Educational Objectives
At the conclusion of this activity, participants should be able to:
  • Describe the pathophysiology of type 2 diabetes and CVD.
  • Review the results of previous strategies addressing CV risk through glucose control.
  • Identify the role of the rosiglitazone controversy in ushering in a new era of CV outcome studies mandated by the Food and Drug Administration (FDA) for type 2 diabetes agents.
  • Summarize the results of cardiovascular outcome trails (CVOTs) of new diabetes agents.
  • Differentiate among agents based on their CV profile.
  • Select an appropriate second agent based on a patient's CV risk profile.